MICI-CMV:Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cytomegalovirus
Relevance of Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cytomegalovirus
Sponsor: University Hospital, Grenoble
Terminated
difficulty to include patients
Other terminated trials from University Hospital, Grenoble
Other Cytomegalovirus Infections trials with similar outcome
Listed as NCT00237653, this PHASE3 trial focuses on Cytomegalovirus Infections and Inflammatory Bowel Diseases and remains terminated or withdrawn. Sponsored by University Hospital, Grenoble, it has been updated 5 times since 2004, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
Feb 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University Hospital, Grenoble
For direct contact, visit the study record on ClinicalTrials.gov .